Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 12/20 | 0.71 |
| ▸ | PPARA | Q07869 | 2/20 | 0.58 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.49 |
| ▸ | CYP4F2 | P78329 | 3/20 | 0.47 |
| ▸ | CYP4A11 | Q02928 | 3/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3657617 | 0.85 | ELANE (0.76) | ELANEPPARA | |
| SCHEMBL9328951 | 0.84 | ELANE (0.69) | ELANE | |
| SCHEMBL18566937 | 0.84 | ELANE (0.69) | ELANEPPARA | |
| SCHEMBL10483720 | 0.83 | ELANE (1.00) | ELANE | |
| SCHEMBL22369614 | 0.82 | ELANE (0.86) | ELANE | |
| SCHEMBL3657615 | 0.81 | ELANE (0.76) | ELANE | |
| SCHEMBL16189796 | 0.81 | ELANE (0.76) | ELANE | |
| SCHEMBL23836711 | 0.81 | ELANE (0.65) | ELANEPPARA | |
| SCHEMBL9299504 | 0.80 | ELANE (0.73) | ELANE | |
| SCHEMBL14870980 | 0.80 | ELANE (0.73) | ELANE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080090827-A1 | Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure | ARTESIAN THERAPEUTICS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| US-20080090827-A1 | Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure | ARTESIAN THERAPEUTICS, INC. (US) | 2008-04-17 | — | — | US | disclosed |
| EP-1830852-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND BETA-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | Artesian Therapeutics, Inc. (US) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006060127-A2 | COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE | ARTESIAN THERAPEUTICS, INC. (US) | 2006-06-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090827-A1 | Compounds With Mixed Pde-Inhibitory and Beta-Adrenergic Antagonist or Partial Agonist Activity For Treatment of Heart Failure | ADRB3, PDE3A, PDE3B | ELANE 3081/4885PPARA 1568/4885PTGS2 636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.